Show simple item record

dc.contributor.authorDungarwalla, M
dc.contributor.authorMatutes, E
dc.contributor.authorDearden, CE
dc.date.accessioned2018-08-30T13:39:51Z
dc.date.issued2008-06
dc.identifier6
dc.identifier.citationEUROPEAN JOURNAL OF HAEMATOLOGY, 2008, 80 pp. 469 - 476
dc.identifier.issn0902-4441
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2429
dc.identifier.eissn1600-0609
dc.identifier.doi10.1111/j.1600-0609.2008.01069.x
dc.description.abstractProlymphocytic leukaemias of B and T cell subtype are rare diseases. Despite recent advances in immunophenotyping and molecular cytogenetics, leading to a better understanding of the underlying cell biology of the prolymphocytic leukaemias, prognosis for these patients remains poor. Purine analogues and monoclonal antibodies have shown efficacy in B-cell prolymphocytic leukaemia although further studies are warranted. Monoclonal antibody therapy with alemtuzumab has significantly improved outcome in T-cell prolymphocytic leukaemia (T-PLL) but responses are still transient and further disease progression is inevitable. While allogeneic stem cell transplant is an attractive option, due to the older age group of T-PLL patients the morbidity and mortality associated with the procedure is significant.
dc.format.extent469 - 476
dc.languageeng
dc.language.isoeng
dc.publisherWILEY
dc.titleProlymphocytic leukaemia of B- and T-cell subtype: a state-of-the-art paper
dc.typeJournal Article
rioxxterms.versionofrecord10.1111/j.1600-0609.2008.01069.x
rioxxterms.licenseref.startdate2008-06
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfEUROPEAN JOURNAL OF HAEMATOLOGY
pubs.notesaffiliation: Dearden, CE (Reprint Author), Royal Marsden Hosp, Dept Haematooncol, Haematooncol Unit, Downs Rd, Sutton SM2 5PT, Surrey, England. Dungarwalla, M.; Matutes, E.; Dearden, C. E., Royal Marsden Hosp, Dept Haematooncol, Haematooncol Unit, Sutton SM2 5PT, Surrey, England. keywords: prolymphocytic leukaemia; cell biology; clinical features; management keywords-plus: CHRONIC LYMPHOCYTIC-LEUKEMIA; ATAXIA-TELANGIECTASIA; ATM GENE; MALIGNANCIES; CAMPATH-1H; CHEMOTHERAPY; EXPRESSION; CLASSIFICATION; TRANSLOCATIONS; ABNORMALITIES research-areas: Hematology web-of-science-categories: Hematology author-email: [email protected] number-of-cited-references: 49 times-cited: 37 usage-count-last-180-days: 0 usage-count-since-2013: 3 journal-iso: Eur. J. Haematol. doc-delivery-number: 298QF unique-id: ISI:000255701500002 oa: gold_or_bronze da: 2018-08-30
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.volume80
pubs.embargo.termsNot known
icr.researchteamMolecular Haematology (including Cytogenetics Group and Cell Markers)en_US
dc.contributor.icrauthorMatutes, Estellaen
dc.contributor.icrauthorDearden, Claireen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record